Petit, A. et al. Novel insights into the mechanism of decreased expression of type X collagen in human mesenchymal stem cells from patients with osteoarthritis cultured on nitrogen-rich plasma polymers: Implication of cyclooxygenase-1. J. Biomed. Mater. Res. A 94, 744–750 (2010).

The certification set forth above is being furnished as an exhibit solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of the annual report on Form 20-F for the period ended December 31, 2018, or as a separate disclosure document of the Company or the certifying officers.

Tran, C. T., Leiper, J. M. & Vallance, P. The DDAH/ADMA/NOS pathway. Atherosclerosis. Supplements 4, 33–40 (2003).

RA PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data)

Forest plot detailing weighted mean difference and 95%Cl for the impact of hydrophilic (left) and hydrophobic (right) statins on plasma concentrations of ADMA. Meta-analysis was performed using a random-effect model with inverse variance weighting.

Actually, slight modifier, mice don’t generally suffer from replicative senescence so the rate of shortening can’t be x90 humans. It must be considerably less than this because they can undergo 4 generations with no TERT before they get short telomere diseases like humans. But DNA replication errors and ROS produce a lot of senescence anyway. And extending telomeres in mice helps avert both this, and the changes of gene expression that cause other problems.

Prof. Ran Oren, M.D. joined our Board in March 2017 and has served as a member of our scientific advisory board since 2014, and as the Company’s Chief Medical Officer from August 1, 2016 to March 14, 2017. Prof. Oren is a Professor of Gastroenterology & Hepatology at the Faculty of Medicine, Hebrew University of Jerusalem, Israel, and is the Head of the Institute of Gastroenterology and Liver Disease at Hadassah Medical Center, Jerusalem, Israel. In addition, Prof. Oren serves as a member of the Scientific Advisory Board of Redhill Biopharma Ltd., a member of the board of directors of the Boxenbaum – Netta Foundation Ltd. (CC), provides consultancy services to MEDecide Ltd., advises Maccabi Healthcare in the field of liver and serves at the editorial board of the official journal of the American Association for the study of liver diseases Hepatology. Prof. Oren published over the years in the fields of liver fibrosis, thyroid hormone, effect on liver diseases and hepatocyte transplantation. In recent years his main research interests are in the field of non-alcoholic fatty liver disease (NAFLD) – epidemiology, risk factors, diagnosis and treatment. Prof. Oren has received numerous academic and professional awards in his field and holds several patents related to the prevention and arresting of human liver disease. In 2000, Prof. Oren established the Liver Unit at the Tel Aviv Sourasky Medical Center, where he served as Chief of Medicine from 2008 to 2010. Prof. Oren concurrently served as the President of the Israeli Association for the Study of the Liver between 2007 and 2010. 

        In the E.U., pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently available therapies. For example, the E.U. provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. E.U. member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the

Oliveira, B. L. et al. Insights into the structural determinants for selective inhibition of nitric oxide synthase isoforms. J. Mol. Model. 19, 1537–1551 (2013).

The left ventricle function was evaluated 1 and 2 months after AAS, respectively, using a Vevo 770 High-Resolution Imaging Systems (Visual Sonics Inc, Toronto, ON, Canada) with a 17.5 MHz linear array transducer. Briefly, rats (n = 6) were anaesthetized with 1.5–2.0% isoflurane. Two-dimensional cine loops and guided M-mode frames were recorded from the parasternal short and long axis12. The following parameters were measured as indicators of cardiac function or remodeling: LVPWd, LVPWs, LVIDs, EF and FS.

        Government authorities in the U.S., at the federal, state, and local level, and in other countries and jurisdictions, including the E.U. and Japan, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the U.S. and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.

This is a bit odd. Both CR and rapamycin will slow proliferation, but end up preserving stem cell function because they reduce senescence. Like you Paul, I can only imagine the rapamycin dose was not intermittent. I’ll watch the video through though, to see what they say.